当前位置:首页 - 行情中心 - 华兰生物(002007) - 财务分析 - 现金流量表

华兰生物

(002007)

  

流通市值:300.40亿  总市值:349.11亿
流通股本:15.74亿   总股本:18.29亿

现金流量表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金5,075,292,993.763,502,067,009.352,440,959,983.731,104,207,859.33
收到的税费返还11,853.9221,579.4121,579.41-
收到其他与经营活动有关的现金72,873,951.6558,365,536.8835,671,747.7213,731,079.93
经营活动现金流入的平衡项目0000
经营活动现金流入小计5,148,178,799.333,560,454,125.642,476,653,310.861,117,938,939.26
购买商品、接受劳务支付的现金1,555,758,240.751,247,456,232.99688,027,496.68301,422,954.86
支付给职工以及为职工支付的现金460,187,211.84351,134,591.75241,024,448.57132,401,574.68
支付的各项税费503,909,131.19343,009,897.77219,837,864.85100,800,895.31
支付其他与经营活动有关的现金1,282,485,434.51926,235,843.26560,379,786.73214,085,725.9
经营活动现金流出的平衡项目0000
经营活动现金流出小计3,802,340,018.292,867,836,565.771,709,269,596.83748,711,150.75
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额1,345,838,781.04692,617,559.87767,383,714.03369,227,788.51
二、投资活动产生的现金流量:
收回投资收到的现金6,407,909,630.244,243,424,737.573,174,649,631.961,539,604,194.16
取得投资收益收到的现金87,943,157.8962,456,067.6748,020,768.9124,969,046.41
处置固定资产、无形资产和其他长期资产收回的现金净额204,113,940.6203,334,862.6203,150,506.6203,108,740.52
投资活动现金流入的平衡项目0000
投资活动现金流入小计6,699,966,728.734,509,215,667.843,425,820,907.471,767,681,981.09
购建固定资产、无形资产和其他长期资产支付的现金753,411,070.78533,953,435.59370,429,887.4182,785,804.24
投资支付的现金6,944,833,339.384,523,156,348.943,260,996,972.262,322,023,999.98
投资活动现金流出的平衡项目0000
投资活动现金流出小计7,698,244,410.165,057,109,784.533,631,426,859.662,504,809,804.22
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-998,277,681.43-547,894,116.69-205,605,952.19-737,127,823.13
三、筹资活动产生的现金流量:
吸收投资收到的现金48,070,638---
取得借款收到的现金700,000,000600,000,000600,000,000-
筹资活动现金流入平衡项目000-
筹资活动现金流入小计748,070,638600,000,000600,000,000-
偿还债务支付的现金600,000,000600,000,000600,000,000-
分配股利、利润或偿付利息支付的现金602,645,246.3598,773,713.85595,409,162.284,710,975.73
其中:子公司支付给少数股东的股利、利润39,003,00039,003,00039,003,000-
支付其他与筹资活动有关的现金380,753.88380,753.88--
筹资活动现金流出平衡项目0000
筹资活动现金流出小计1,203,026,000.181,199,154,467.731,195,409,162.284,710,975.73
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-454,955,362.18-599,154,467.73-595,409,162.28-4,710,975.73
四、汇率变动对现金及现金等价物的影响63,317.76-85.1418,006.58-130.03
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-107,330,944.81-454,431,109.69-33,613,393.86-372,611,140.38
加:期初现金及现金等价物余额1,096,655,560.321,096,655,560.321,096,655,560.321,096,655,560.32
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额989,324,615.51642,224,450.631,063,042,166.46724,044,419.94
补充资料:
净利润1,761,684,894.67-562,105,139.26-
资产减值准备90,878,652.81--4,041,679.17-
固定资产和投资性房地产折旧247,856,077.89-121,796,877.96-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧247,856,077.89-121,796,877.96-
无形资产摊销11,196,999.64-5,537,974.4-
长期待摊费用摊销14,196,045.55-7,451,256.81-
处置固定资产、无形资产和其他长期资产的损失-44,443,673.01--43,601,783.04-
固定资产报废损失9,714,357.33-7,863,706.78-
公允价值变动损失-60,544,227.95--35,321,806.08-
财务费用13,388,622.2-9,163,691.5-
投资损失-149,045,587.36--77,430,398.19-
递延所得税12,809,351.19-14,628,082.1-
其中:递延所得税资产减少-11,647,623.77-2,921,222.13-
递延所得税负债增加24,456,974.96-11,706,859.97-
存货的减少-316,446,740.83--347,823,613.17-
经营性应收项目的减少-302,658,069.41-883,011,696.88-
经营性应付项目的增加7,973,745.97--309,905,273.36-
其他35,324,175.73-14,403,566.36-
现金的期末余额989,324,615.51-1,063,042,166.46-
减:现金的期初余额1,096,655,560.32-1,096,655,560.32-
公告日期2024-03-302023-10-302023-08-242023-04-22
审计意见(境内)标准无保留意见
TOP↑